Key result
Low-dose cyclosporine plus phosphoramidon extends rat cardiac allograft survival by ~31 days vs controls.
Why the study?
Endothelin-1 blockade attenuates transplant vasculopathy and chronic allograft dysfunction, and combining endothelin-converting enzyme inhibition with low-dose cyclosporine may improve allograft survival while reducing cyclosporine side effects.
Does the combination of phosphoramidon and low-dose cyclosporine improve survival in rat cardiac allografts?
Population
Lewis to Fisher 344 rat heterotopic cardiac allografts
Comparison
Untreated vs high-dose CsA vs low-dose CsA vs phosphoramidon vs low-dose CsA plus phosphoramidon
Design
Preclinical experimental study
Follow-up
Median survival up to 47 days
Authors
Loading...
Hypothesis-generating for endothelin inhibition with low-dose cyclosporine in transplantation; leaves open translation to clinical allograft outcomes.
Does the combination of phosphoramidon and low-dose cyclosporine improve survival in rat cardiac allografts?
Absolute Event Rate: 47% vs 16%
p-value: p=<0.01
Combining low-dose cyclosporine with endothelin-converting enzyme inhibition improves long-term cardiac allograft survival and reduces vasculopathy in a rat model.
Simonson et al. (2002) studied Cardiac allograft transplantation. Phosphoramidon and low-dose cyclosporine vs. Untreated, high-dose cyclosporine, low-dose cyclosporine alone, or phosphoramidon alone was evaluated on Median survival (days) (p=<0.01). Combination therapy with low-dose cyclosporine and phosphoramidon improved median survival of rat cardiac allografts to 47 days compared to 16 days in untreated controls (P<0.01).
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: